Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: A pre-specified analysis from the SELECT trial

Back

HFA Premium Access

Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: A pre-specified analysis from the SELECT trial

Session: Late breaking clinical trials II

Topic: Pharmacotherapy

Speaker: Professor J. Deanfield (London, GB)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)

53 presentations

3 followers

9 more presentations in this session

Transendocardial injection of autologous expanded CD34+ Stem Cells (ProtheraCytes) promotes reverse cardiac remodeling in patients with left ventricular dysfunction after acute myocardial infarction

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Access

Slides

Video

Discussant review - EXCELLENT

Speaker: Professor F. Gustafsson (Copenhagen, DK)

Access

Slides

Video

Bio-ADM as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure; data from STRONG-HF

Speaker: Mr G. Voordes (Groningen, NL)

Access

Slides

Video

Discussant review - STRONG-HF

Speaker: Doctor A. Bayes Genis (Badalona, ES)

Access

Slides

Video

Discussant review - SELECT

Speaker: Professor P. Jhund (Glasgow, GB)

Access

Slides

Video

Access the full session

Late breaking clinical trials II

Speakers: Professor J. Deanfield, Professor F. Zannad, Professor F. Gustafsson, Mr G. Voordes, Doctor A. Bayes Genis...

Access

Video

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources